Amarin Corp Plc (AMRN)

[lbwagain]

New poster, long time reader of the blog. just found this:

Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients
9 minutes ago by CNW Group
Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD") and overall health, announced today the publication of results of a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN(®) in the correction of Omega-3 deficiency in patients with one or more risk factors associated with CVD and evaluated VASCAZEN(®)'s concomitant effects on these risk factors including triglycerides, VLDL cholesterol, LDL cholesterol, and HDL cholesterol.

The publication titled, "Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®)-REVEAL Trial," was authored by Nisar Shaikh, Jason Yantha, Sabah Shaikh, William Rowe, Maggie Laidlaw, Carla Cockerline, Abbas Ali, Bruce Holub and George Jackowski, and is now available in the peer-reviewed journal titled Molecular and Cellular Biochemistry (MCB) with open public access at http://link.springer.com/article/10.1007/s11010-014-2132-1/fulltext.html.

Of the 655 patients screened 89% were Omega-3 deficient. The VASCAZEN(®)-REVEAL trial was the first to determine levels of Omega-3 in plasma and in red blood cells using the Omega-Score and Omega-Index diagnostics. Omega-Score measures blood levels of EPA, DHA and DPA and Omega-Index measures EPA and DHA in red blood cells. VASCAZEN(®) was demonstrated to be highly effective in correcting an Omega-3 deficiency in CVD patients with normal and high triglycerides. In eight weeks of treatment with 4 capsules/day of VASCAZEN(®) there was a 121% improvement in the Omega-Score and 112% improvement in Omega-Index in CVD patients with hypertriglyceridemia (200-500 mg/dL). The VASCAZEN(®) formulation had a profound effect on correcting an Omega-3 deficiency and positive effect on lipid profiles, mainly the reduction of triglycerides and raising HDL in as little as eight weeks of treatment.

Treatment with VASCAZEN(®) was associated with a 48% reduction in triglycerides, a 30% reduction in VLDL-C and a 9% increase in HDL-C without adversely affecting LDL-C in patients with hypertriglyceridemia. The safety profile of VASCAZEN(®) was similar to placebo with no treatment related serious adverse events reported in the trial.

Dr. George Jackowski, Chief Scientific Officer and co-author of the MCB paper said, "Clinical evidence continues to highlight VASCAZEN(®)'s unique and proprietary Omega-3 formulation and we believe that the publication of this trial represents further peer-reviewed validation of VASCAZEN(®) as an effective medical food for correcting an Omega-3 deficiency."